Orient Pharma Co Ltd

Orient Pharma Co Ltd maintains a strong liquidity position, with a current ratio of 6.73, indicating that the company has sufficient current assets to cover its current liabilities multiple times over. The company also holds TWD 460 million in cash and equivalents, which provides a buffer against short-term financial obligations. The debt-to-equity ratio is 0.08, suggesting that the company is largely equity-funded and has minimal leverage. In terms of profitability, Orient Pharma Co Ltd reports a return on equity (ROE) of 8.13% and a return on assets (ROA) of 7.09%, both of which are strong indicators of efficient capital use and profitability. These metrics are in line with the typical performance of pharmaceutical companies, which often benefit from high gross margins and stable demand for essential medicines. The company's revenue is not segmented by product or geographic region in the available data, but the overall revenue of TWD 1.4 billion suggests a broad customer base and product portfolio. Given the absence of specific geographic breakdowns, it is unclear whether the company is heavily concentrated in any one region, but the pharmaceutical industry typically benefits from diversified markets. Looking ahead, the company's growth trajectory is supported by its strong operating cash flow of TWD 359.86 million and free cash flow of TWD 294.55 million, which can be reinvested into the business or used to fund expansion. The capital expenditure of TWD -49.495 million indicates that the company is not currently investing heavily in new infrastructure, which may suggest a focus on maintaining existing operations rather than aggressive expansion. The risk assessment for Orient Pharma Co Ltd indicates a low level of liquidity and dilution risk, with no immediate filing-based flags detected. The company's low debt levels and strong cash reserves reduce the likelihood of financial distress, and the absence of dilution risk suggests that the company is not planning to issue additional shares in the near term. Recent events, including filings and transcripts, do not indicate any material changes in the company's financial or operational status. The company appears to be operating in a stable environment, with no significant regulatory or market disruptions reported in the latest available data.